Monday, November 9, 2026

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

CHARLESTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. 

SGT-212 for Friedreich's ataxia (FA) Five participants have been dosed with SGT-212 in the Phase 1b FALCON clinical trial, with no treatment-related serious adverse events observed as of November 3, 2026. Participant screening and enrollment remain ongoing, and Solid expects to report initial data in the first quarter of 2027, subject to participant enrollment. 

In October, SGT-212 received Orphan designation for the treatment of Friedreich's ataxia from the European Commission, acting upon the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products.